SHP2 was also identified as a key factor that promotes MEK/ERK pathway activation and therapy resistance in ALK and KRAS mutant non-small-cell lung cancers (NSCLC) [33, 34]. The gene discussed is PTPN11; the disease is non-small cell lung carcinoma.